Current Osteoporosis Reports

, Volume 10, Issue 1, pp 48–55 | Cite as

Osteoporosis After Transplantation

  • Carolina A. Moreira Kulak
  • Victoria Z. Cochenski Borba
  • Jaime Kulak Júnior
  • Melani Ribeiro Custódio
Current Therapeutics (SL Silverman, Section Editor)


Transplantation is an established therapy for end-stage diseases of kidney, lung, liver, and heart among others. Osteoporosis and fragility fractures are serious complications of organ transplantation, particularly in the first post-transplant year. Many factors contribute to the pathogenesis of osteoporosis following organ transplantation. This review addresses the mechanisms of bone loss that occurs both in the early and late post-transplant periods, including the contribution of the immunosuppressive agents as well as the specific features to bone loss after kidney, lung, liver, cardiac, and bone marrow transplantation. Prevention and treatment for osteoporosis in the transplant recipient are also discussed.


Secondary osteoporosis Transplantation Immunosuppressive agents Bone loss 



Conflicts of interest: C.A.M Kulak: none; V.Z.C Borba: has received payment for development of educational presentations including service on speakers’ bureaus from Novartis, and has received travel/accommodations expenses covered or reimbursed from Eli Lilly; J. Kulak Jr: none; M.R. Custódio: has received payment for development of educational presentations including service on speakers’ bureaus from Abbott and Amgen.


Papers of particular interest, published recently, have been highlighted as:• Of importance •• Of major importance

  1. 1.
    Kulak CA, Borba VZ, Kulak Junior J, Campos DJ, Shane E. Post-transplantation osteoporosis. Arq Bras Endocrinol Metabol. 2010;54(2):143–9.PubMedGoogle Scholar
  2. 2.
    Stein E, Ebeling P, Shane E. Post-transplantation osteoporosis. Endocrinol Metab Clin North Am. 2007;36(4):937–63. viii.PubMedCrossRefGoogle Scholar
  3. 3.
    Epstein S. Post-transplantation bone disease: the role of immunosuppressive agents and the skeleton. J Bone Miner Res. 1996;11(1):1–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Julian BA, Laskow DA, Dubovsky J, Dubovsky EV, Curtis JJ, Quarles LD. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med. 1991;325(8):544–50.PubMedCrossRefGoogle Scholar
  5. 5.
    Canalis E, Delany AM. Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci. 2002;966:73–81.PubMedCrossRefGoogle Scholar
  6. 6.
    Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998;102(2):274–82.PubMedCrossRefGoogle Scholar
  7. 7.
    Sakakura M, Takebe K, Nakagawa S. Inhibition of luteinizing hormone secretion induced by synthetic LRH by long-term treatment with glucocorticoids in human subjects. J Clin Endocrinol Metab. 1975;40(5):774–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Suzuki Y, Ichikawa Y, Saito E, Homma M. Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism. 1983;32(2):151–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Peeters GM, van Schoor NM, van Rossum EF, Visser M, Lips P. The relationship between cortisol, muscle mass and muscle strength in older persons and the role of genetic variations in the glucocorticoid receptor. Clin Endocrinol (Oxf). 2008;69(4):673–82.CrossRefGoogle Scholar
  10. 10.
    Sun L, Peng Y, Zaidi N, Zhu LL, Iqbal J, Yamoah K, et al. Evidence that calcineurin is required for the genesis of bone-resorbing osteoclasts. Am J Physiol Renal Physiol. 2007;292(1):F285–91.PubMedCrossRefGoogle Scholar
  11. 11.
    Josephson MA, Schumm LP, Chiu MY, Marshall C, Thistlethwaite JR, Sprague SM. Calcium and calcitriol prophylaxis attenuates posttransplant bone loss. Transplantation. 2004;78(8):1233–6.PubMedCrossRefGoogle Scholar
  12. 12.
    McIntyre HD, Menzies B, Rigby R, Perry-Keene DA, Hawley CM, Hardie IR. Long-term bone loss after renal transplantation: comparison of immunosuppressive regimens. Clin Transplant. 1995;9(1):20–4.PubMedGoogle Scholar
  13. 13.
    Goffin E, Devogelaer JP, Lalaoui A, Depresseux G, De Naeyer P, Squifflet JP, et al. Tacrolimus and low-dose steroid immunosuppression preserves bone mass after renal transplantation. Transpl Int. 2002;15(2–3):73–80.PubMedCrossRefGoogle Scholar
  14. 14.
    Monegal A, Navasa M, Guanabens N, Peris P, Pons F, de Osaba MJ Martinez, et al. Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine A. Calcif Tissue Int. 2001;68(2):83–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Hruska KA, Teitelbaum SL. Renal osteodystrophy. N Engl J Med. 1995;333(3):166–74.PubMedCrossRefGoogle Scholar
  16. 16.
    Evenepoel P, Claes K, Kuypers D, Maes B, Bammens B, Vanrenterghem Y. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrol Dial Transplant. 2004;19(5):1281–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, Proudfoot D, et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol. 2004;15(11):2857–67.PubMedCrossRefGoogle Scholar
  18. 18.
    Koch Nogueira PC, David L, Cochat P. Evolution of secondary hyperparathyroidism after renal transplantation. Pediatr Nephrol. 2000;14(4):342–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Kwan JT, Almond MK, Evans K, Cunningham J. Changes in total body bone mineral content and regional bone mineral density in renal patients following renal transplantation. Miner Electrolyte Metab. 1992;18(2–5):166–8.PubMedGoogle Scholar
  20. 20.
    Nisbeth U, Lindh E, Ljunghall S, Backman U, Fellstrom B. Increased fracture rate in diabetes mellitus and females after renal transplantation. Transplantation. 1999;67(9):1218–22.PubMedCrossRefGoogle Scholar
  21. 21.
    Abbott KC, Oglesby RJ, Hypolite IO, Kirk AD, Ko CW, Welch PG, et al. Hospitalizations for fractures after renal transplantation in the United States. Ann Epidemiol. 2001;11(7):450–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Jastrzebski D, Lutogniewska W, Ochman M, Margas A, Kowalski K, Wyrwol J, et al. Osteoporosis in patients referred for lung transplantation. Eur J Med Res. 2010;15 Suppl 2:68–71.PubMedGoogle Scholar
  23. 23.
    Franco CB, Paz-Filho G, Gomes PE, Nascimento VB, Kulak CA, Boguszewski CL, et al. Chronic obstructive pulmonary disease is associated with osteoporosis and low levels of vitamin D. Osteoporos Int. 2009;20(11):1881–7.PubMedCrossRefGoogle Scholar
  24. 24.
    •• Kulak CA BV, Jorgetti, V, Dos Reis LM, Liu XS, Kimmel DB, Kulak J Jr, Rabelo LM, Zhou H, Guo XE, Bilezikian JP, Boguszewski CL, Dempster DW. Skeletal microstructural abnormalities in postmenopausal women with chronic obstructive pulmonary disease. J Bone Miner Res. 2010;9(25):1931–40. In this study it was demonstrated that COPD patients present with microarchitecture deterioration before transplant, and it was related to the amount of smoking. CrossRefGoogle Scholar
  25. 25.
    Spira A, Gutierrez C, Chaparro C, Hutcheon MA, Chan CK. Osteoporosis and lung transplantation: a prospective study. Chest. 2000;117(2):476–81.PubMedCrossRefGoogle Scholar
  26. 26.
    Ferrari SL, Nicod LP, Hamacher J, Spiliopoulos A, Slosman DO, Rochat T, et al. Osteoporosis in patients undergoing lung transplantation. Eur Respir J. 1996;9(11):2378–82.PubMedCrossRefGoogle Scholar
  27. 27.
    Shane E, Silverberg SJ, Donovan D, Papadopoulos A, Staron RB, Addesso V, et al. Osteoporosis in lung transplantation candidates with end-stage pulmonary disease. Am J Med. 1996;101(3):262–9.PubMedCrossRefGoogle Scholar
  28. 28.
    • Stein EM, Cohen A, Freeby M, Rogers H, Kokolus S, Scott V, et al. Severe vitamin D deficiency among heart and liver transplant recipients. Clin Transplant. 2009 Nov-Dec;23(6):861–5. This study demonstrates that vitamin D deficiency is highly prevalent among heart and liver transplant recipients. Ninety-one percent had levels below 75 nmol/L, with the liver recipient patients at greatest risk. PubMedCrossRefGoogle Scholar
  29. 29.
    •• Dalle Carbonare L, Zanatta M, Braga V, Sella S, Vilei MT, Feltrin G, et al. Densitometric threshold and vertebral fractures in heart transplant patients. Transplantation. 2011 Jul 15;92(1):106–11. This is a cross-sectional study in 180 heart transplant patients showing that standard densitometric criteria were unreliable to identify bone fragility. PubMedCrossRefGoogle Scholar
  30. 30.
    Shane E, Rivas M, Staron RB, Silverberg SJ, Seibel MJ, Kuiper J, et al. Fracture after cardiac transplantation: a prospective longitudinal study. J Clin Endocrinol Metab. 1996;81(5):1740–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Sachdeva R, Soora R, Bryant JC, Seibert JJ, Blaszak RT, Frazier EA. Bone mineral status in pediatric heart transplant recipients: a retrospective observational study of an “at risk” cohort. Pediatr Transplant. 2010;14(3):383–7.PubMedCrossRefGoogle Scholar
  32. 32.
    • McClune BL, Polgreen LE, Burmeister LA, Blaes AH, Mulrooney DA, Burns LJ, et al. Screening, prevention and management of osteoporosis and bone loss in adult and pediatric hematopoietic cell transplant recipients. Bone Marrow Transplant. 2011;Jan;46(1):1–9. In this paper, the authors recommend screening all adult allogeneic and autologous hematopoietic cell transplantation patients with DXA 1 year after transplantation as well as pediatric patients at risk for bone loss. PubMedCrossRefGoogle Scholar
  33. 33.
    Schulte CM, Beelen DW. Bone loss following hematopoietic stem cell transplantation: a long-term follow-up. Blood. 2004;103(10):3635–43.PubMedCrossRefGoogle Scholar
  34. 34.
    Leeuwin RS, Njio KD, Belling GA, van den Hoven S. Glucocorticoid-induced changes in synaptic vesicles of rat phrenic nerve terminals. Arch Int Pharmacodyn Ther. 1983;266(2):200–7.PubMedGoogle Scholar
  35. 35.
    • Faulhaber GA, Premaor MO, Moser Filho HL, Silla LM, Furlanetto TW. Low bone mineral density is associated with insulin resistance in bone marrow transplant subjects. Bone Marrow Transplant. 2009 Jun;43(12):953–7. This study shows that insulin resistance, low vitamin D, and ferritin levels were associated with low bone mass in bone marrow recipient patients. PubMedCrossRefGoogle Scholar
  36. 36.
    Kreutz M, Eissner G, Hahn J, Andreesen R, Drobnik W, Holler E. Variations in 1 alpha,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 serum levels during allogeneic bone marrow transplantation. Bone Marrow Transplant. 2004;33(8):871–3.PubMedCrossRefGoogle Scholar
  37. 37.
    Compston JE. Osteoporosis after liver transplantation. Liver Transpl. 2003;9(4):321–30.PubMedCrossRefGoogle Scholar
  38. 38.
    Ninkovic M, Love S, Tom BD, Bearcroft PW, Alexander GJ, Compston JE. Lack of effect of intravenous pamidronate on fracture incidence and bone mineral density after orthotopic liver transplantation. J Hepatol. 2002;37(1):93–100.PubMedCrossRefGoogle Scholar
  39. 39.
    Monegal A, Navasa M, Guanabens N, Peris P, Pons F, de Osaba MJ Martinez, et al. Bone disease after liver transplantation: a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics. Osteoporos Int. 2001;12(6):484–92.PubMedCrossRefGoogle Scholar
  40. 40.
    • Baccaro LF, Boin IF, Pedro AO, Costa-Paiva L, Leal AL, Ramos CD, et al. Decrease in bone mass in women after liver transplantation: associated factors. Transplant Proc. 2011 May;43(4):1351–6. This study shows that estrogen prevents bone loss in premenopausal women after transplantation. PubMedCrossRefGoogle Scholar
  41. 41.
    Fabrega E, Orive A, Garcia-Unzueta M, Amado JA, Casafont F, Pons-Romero F. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand system in the early post-operative period of liver transplantation. Clin Transplant. 2006;20(3):383–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Querings K, Girndt M, Geisel J, Georg T, Tilgen W, Reichrath J. 25-hydroxyvitamin D deficiency in renal transplant recipients. J Clin Endocrinol Metab. 2006;91(2):526–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Akeno N, Matsunuma A, Maeda T, Kawane T, Horiuchi N. Regulation of vitamin D-1alpha-hydroxylase and −24-hydroxylase expression by dexamethasone in mouse kidney. J Endocrinol. 2000;164(3):339–48.PubMedCrossRefGoogle Scholar
  44. 44.
    Reichrath J. Dermatologic management, sun avoidance and vitamin D status in organ transplant recipients (OTR). J Photochem Photobiol B. 2010;101(2):150–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Briffa NK, Keogh AM, Sambrook PN, Eisman JA. Reduction of immunosuppressant therapy requirement in heart transplantation by calcitriol. Transplantation. 2003;75(12):2133–4.PubMedCrossRefGoogle Scholar
  46. 46.
    El-Agroudy AE, El-Husseini AA, El-Sayed M, Mohsen T, Ghoneim MA. A prospective randomized study for prevention of postrenal transplantation bone loss. Kidney Int. 2005;67(5):2039–45.PubMedCrossRefGoogle Scholar
  47. 47.
    Isoniemi H, Appelberg J, Nilsson CG, Makela P, Risteli J, Hockerstedt K. Transdermal oestrogen therapy protects postmenopausal liver transplant women from osteoporosis. A 2-year follow-up study. J Hepatol. 2001;34(2):299–305.PubMedCrossRefGoogle Scholar
  48. 48.
    Tierney KD, Facione N, Padilla G, Blume K, Dodd M. Altered sexual health and quality of life in women prior to hematopoietic cell transplantation. Eur J Oncol Nurs. 2007;11(4):298–308.PubMedCrossRefGoogle Scholar
  49. 49.
    D’Souza AB, Grigg AP, Szer J, Ebeling PR. Zoledronic acid prevents bone loss after allogeneic haemopoietic stem cell transplantation. Intern Med J. 2006;36(9):600–3.PubMedCrossRefGoogle Scholar
  50. 50.
    Coco M, Glicklich D, Faugere MC, Burris L, Bognar I, Durkin P, et al. Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol. 2003;14(10):2669–76.PubMedCrossRefGoogle Scholar
  51. 51.
    Crawford BA, Kam C, Pavlovic J, Byth K, Handelsman DJ, Angus PW, et al. Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2006;144(4):239–48.PubMedGoogle Scholar
  52. 52.
    Giannini S, D’Angelo A, Carraro G, Nobile M, Rigotti P, Bonfante L, et al. Alendronate prevents further bone loss in renal transplant recipients. J Bone Miner Res. 2001;16(11):2111–7.PubMedCrossRefGoogle Scholar
  53. 53.
    Shane E, Addesso V, Namerow PB, McMahon DJ, Lo SH, Staron RB, et al. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med. 2004;350(8):767–76.PubMedCrossRefGoogle Scholar
  54. 54.
    Pennisi P, Trombetti A, Giostra E, Mentha G, Rizzoli R, Fiore CE. Pamidronate and osteoporosis prevention in liver transplant recipients. Rheumatol Int. 2007;27(3):251–6.PubMedCrossRefGoogle Scholar
  55. 55.
    Krieg MA, Seydoux C, Sandini L, Goy JJ, Berguer DG, Thiebaud D, et al. Intravenous pamidronate as treatment for osteoporosis after heart transplantation: a prospective study. Osteoporos Int. 2001;12(2):112–6.PubMedCrossRefGoogle Scholar
  56. 56.
    Palmer SC, McGregor DO, Strippoli GF. Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database Syst Rev. 2007(3):CD005015.Google Scholar
  57. 57.
    Malluche HH, Monier-Faugere MC, Herberth J. Bone disease after renal transplantation. Nat Rev Nephrol. 2010;6(1):32–40.PubMedCrossRefGoogle Scholar
  58. 58.
    Cejka D, Benesch T, Krestan C, Roschger P, Klaushofer K, Pietschmann P, et al. Effect of teriparatide on early bone loss after kidney transplantation. Am J Transplant. 2008;8(9):1864–70.PubMedCrossRefGoogle Scholar
  59. 59.
    •• Stein EM, Ortiz D, Jin Z, McMahon DJ, Shane E. Prevention of Fractures after Solid Organ Transplantation: A Meta-Analysis. J Clin Endocrinol Metab. 2011 Aug 17. This is an important meta-analysis regarding the results from treatment with vitamin D and BPs after transplantation on the reduction of fractures. Google Scholar
  60. 60.
    Kulak CAM, Shane E: Transplantation Osteoporosis: biochemical Correlates of Pathogenesis and Treatment. In Dynamics of Bone and Cartilage Metabolism, 2nd edition. Edited by Seibel MJ, Robins SP, Bilezikian JP. Philadelphia: Elsevier; 2006:701–716.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Carolina A. Moreira Kulak
    • 1
    • 3
  • Victoria Z. Cochenski Borba
    • 2
    • 3
  • Jaime Kulak Júnior
    • 4
  • Melani Ribeiro Custódio
    • 5
  1. 1.Division of Endocrinology & Metabolism of Hospital de Clínicas - SEMPRFederal University of ParanaCuritibaBrazil
  2. 2.Endocrinology Division of Hospital de ClinicasFederal University of Parana Serviço de Endocrinologia e Metabologia HC-UFPR (SEMPR)Q1 CuritibaBrazil
  3. 3.Department of Internal MedicineFederal University of ParanaCuritibaBrazil
  4. 4.Department of Obstetrics & GynecologyFederal University of ParanaCuritibaBrazil
  5. 5.Department of Internal MedicineNephrology Division, Universidade de São PauloSão PauloBrazil

Personalised recommendations